At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 133 enrolled
Drug / intervention
Prexasertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Prexasertib for Small Cell Lung Cancer. Completed, enrolled 133 participants across 41 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesFrance, Germany, Greece, Netherlands, South Korea, Spain, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionJul 2017
Study CompletionFeb 2019
TodayJul 2026
First PostedApr 13, 2016
Enrollment StartMay 11, 2016
Primary CompletionJul 31, 2017
Study CompletionFeb 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.2 years ago
Interventions
Prexasertibdrug
Administered IV